People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care.

Advanced sensing features are coming to wearables beginning in 2025 and Penn State’s device, made with laser-modified ...

Insulin pumps and CGMS provide greater flexibility, improved blood sugar control, and better quality of life for children and ...

Germantown, Maryland Monday, February 10, 2025, 16:00 Hrs [IST] ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq ...

U.S. officials are warning about a potentially life-threatening issue with smartphone apps that help manage diabetes.